Tag: synergy therapy
-

CRE Acquisition After Colistin Monotherapy vs Colistin-Meropenem: Insights from the AIDA Trial
Overview Carbapenem-resistant Enterobacterales (CRE) infections pose a major challenge across healthcare settings due to limited treatment options and high mortality. The AIDA randomized trial investigates how initial treatment choices—specifically colistin monotherapy versus a combination of colistin with meropenem—may influence subsequent acquisition and molecular characteristics of CRE isolates. This article summarizes the study’s aims, methods, key…
